UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Abstract PO2-03-08: Uncovering Novel Potential Prognostic Biomarkers in Basal-Like Breast Cancer using Transcriptomic Data of 1,899 Patients

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9_Supplement), p.PO2-03-08-PO2-03-08

2024

Volltextzugriff (PDF)

Abstract PO2-03-07: Immune Landscape in PD-L1-positive and TROP2-positive Triple-Negative Breast Cancer

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9_Supplement), p.PO2-03-07-PO2-03-07

2024

Volltextzugriff (PDF)

Erratum To: Prolyl‐isomerase Pin1 controls normal and cancer stem cells of the breast

EMBO molecular medicine, 2014-05, Vol.6 (5), p.702-702

2014

Volltextzugriff (PDF)

Abstract P5-02-04: Immune Signatures Display Subtype-Specific Activation in Breast Cancer

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.P5-P5-02-04

2023

Volltextzugriff (PDF)

Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS1108-TPS1108

2022

Volltextzugriff (PDF)

HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS1115-TPS1115

2023

Volltextzugriff (PDF)

Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers

Current pharmaceutical design, 2012-12, Vol.19 (5), p.864-882

2012

Volltextzugriff (PDF)

Immune gene signatures in triple-negative breast cancers characterized by varying levels of chromosomal instability

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.1096-1096

2017

Volltextzugriff (PDF)

Erratum to “Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma” [Hum Pathol 40 (2009) 827-833]

Human pathology, 2009-08, Vol.40 (8), p.1212-1212

2009

Volltextzugriff (PDF)

Primary growth hormone insensitivity (Laron syndrome) and acquired hypothyroidism: a case report

Journal of medical case reports, 2011-07, Vol.5 (1), p.301-301, Article 301

2011

Volltextzugriff (PDF)

Abstract A118: CD103+/PD-1+ T-cells identify a subset of triple-negative breast cancer eligible for targeted checkpoint inhibition

Cancer immunology research, 2016-11, Vol.4 (11_Supplement), p.A118-A118

2016

Volltextzugriff (PDF)

Abstract 1958: Developing an online tool to validate survival-associated miRNAs utilizing expression data from 2,061 breast cancer patients

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.1958-1958

2016

Volltextzugriff (PDF)

Abstract PO1-19-11: Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for HER2+ Metastatic Breast Cancer (HER2CLIMB-05, Trial in Progress)

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9_Supplement), p.PO1-19-11-PO1-19-11

2024

Volltextzugriff (PDF)

miRNAs in Medullary Thyroid Carcinoma: When will they be Relevant to the Clinic?

International journal of endocrine oncology, 2014-08, Vol.1 (1), p.7-10

2014

Volltextzugriff (PDF)

Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) + trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9593-9593

2020

Volltextzugriff (PDF)

Abstract CT065: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT065-CT065

2023

Volltextzugriff (PDF)

Abstract OT2-16-03: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.OT2-16-03-OT2-16-03

2023

Volltextzugriff (PDF)

Abstract P4-07-02: A large integrated-gene profiling analysis identifies prognostic microRNAs and correlated DNA repair genes in estrogen receptor positive and negative breast cancers

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.P4-P4-07-02

2015

Volltextzugriff (PDF)

Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes: Prognostic value of methylation in breast cancer subtypes

International journal of cancer, 2016-01, Vol.138 (1), p.87-97

2016

Volltextzugriff (PDF)

A circulating miRNA signature to implement diagnostic imaging analysis in young early-stage breast cancer patients

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.11562-11562

2016

Volltextzugriff (PDF)

AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients

NPJ breast cancer, 2016-11, Vol.2 (1), p.16033-16033, Article 16033

2016

Volltextzugriff (PDF)

Triple negative breast cancer: a heterogeneous subgroup denned by what it is not

European journal of cancer (1990), 2011-09, Vol.47, p.S370-S372

2011

Volltextzugriff (PDF)

An immune-related signature for prediction of risk of late recurrences beyond proliferation and ER-related genes in ER-positive breast cancer

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.530-530

2014

Volltextzugriff (PDF)

Prolyl‐isomerase Pin1 controls normal and cancer stem cells of the breast

EMBO molecular medicine, 2014-05, Vol.6 (5), p.702-702

2014

Volltextzugriff (PDF)

E16. Clinical implications of microRNAs in breast cancer

European journal of cancer (1990), 2012-03, Vol.48, p.S32-S34

2012

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

ThemaTumors

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(31)

Publikationsform

Sprache

Englisch
(38)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(7)
Oncology
(7)
Science & Technology
(7)
Breast Cancer
(4)
Hematology, Oncology And Palliative Medicine
(4)
692/4028/67/1347
(1)
692/53/2422
(1)
Anthracycline
(1)
Anthracyclines
(1)
Aromatase Inhibitor Resistance
(1)
Biomarkers
(1)
Biomedical And Life Sciences
(1)
Biomedicine
(1)
Bone Metastasis
(1)
Breast
(1)
Calcitonin
(1)
Cancer Research
(1)
Care And Treatment
(1)
Case Report
(1)
Case Studies
(1)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Abstract PO2-03-08: Uncovering Novel Potential Prognostic Biomarkers in Basal-Like Breast Cancer using Transcriptomic Data of 1,899 Patients

Abstract PO2-03-07: Immune Landscape in PD-L1-positive and TROP2-positive Triple-Negative Breast Cancer

Erratum To: Prolyl‐isomerase Pin1 controls normal and cancer stem cells of the breast

Abstract P5-02-04: Immune Signatures Display Subtype-Specific Activation in Breast Cancer

Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)

HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer

Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers

Immune gene signatures in triple-negative breast cancers characterized by varying levels of chromosomal instability

Erratum to “Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma” [Hum Pathol 40 (2009) 827-833]

Primary growth hormone insensitivity (Laron syndrome) and acquired hypothyroidism: a case report

Abstract A118: CD103+/PD-1+ T-cells identify a subset of triple-negative breast cancer eligible for targeted checkpoint inhibition

Abstract 1958: Developing an online tool to validate survival-associated miRNAs utilizing expression data from 2,061 breast cancer patients

Abstract PO1-19-11: Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for HER2+ Metastatic Breast Cancer (HER2CLIMB-05, Trial in Progress)

miRNAs in Medullary Thyroid Carcinoma: When will they be Relevant to the Clinic?

Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) + trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC)

Abstract CT065: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)

Abstract OT2-16-03: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)

Abstract P4-07-02: A large integrated-gene profiling analysis identifies prognostic microRNAs and correlated DNA repair genes in estrogen receptor positive and negative breast cancers

Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes: Prognostic value of methylation in breast cancer subtypes

A circulating miRNA signature to implement diagnostic imaging analysis in young early-stage breast cancer patients

AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients

Triple negative breast cancer: a heterogeneous subgroup denned by what it is not

An immune-related signature for prediction of risk of late recurrences beyond proliferation and ER-related genes in ER-positive breast cancer

Prolyl‐isomerase Pin1 controls normal and cancer stem cells of the breast

E16. Clinical implications of microRNAs in breast cancer

Aktive Filter

Suchergebnisse filtern